[ST Wanbang: Subsidiary's new ALS drug WP205 has been approved by the FDA to support Phase III clinical trials] On October 29, ST Wanbang (002082.SZ) announced that the company's wholly-owned subsidiary Wanbang Pharmaceutical Group received written feedback from the U.S. FDA on the plan to launch a key registration phase III clinical trial for the new ALS drug WP205 (methylcobalamin injection). The FDA basically recognizes the existing pharmacological and toxicological data and research content, and will fully support the launch of the trial and provide guidance and suggestions on the details of the Phase III clinical program. The company stated that the conclusion of this communication will not have a significant impact on operating performance in the short term, and there are uncertainties in drug research and development. Investors are advised to pay attention to the risks.